Hospital.Help

Berlin – The current supply bottlenecks for the GLP-1 receptor antagonist Ozempic (semaglutide) are expected to continue until the end of the year. This was stated by the manufacturer Novo Nordisk in response to a request from the German Medical Journal. In July, the company had… [weiter lesen]

#Ozempic #bottlenecks #year